PRESS RELEASE published on 07/21/2023 at 15:21, 2 years 8 months ago EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
PRESS RELEASE published on 06/08/2023 at 11:31, 2 years 9 months ago Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
PRESS RELEASE published on 06/07/2023 at 17:18, 2 years 9 months ago ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
PRESS RELEASE published on 05/30/2023 at 13:00, 2 years 9 months ago Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
PRESS RELEASE published on 05/15/2023 at 09:27, 2 years 10 months ago Reorganization in the Executive Board of Eckert & Ziegler
PRESS RELEASE published on 05/11/2023 at 07:45, 2 years 10 months ago Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
PRESS RELEASE published on 05/08/2023 at 11:15, 2 years 10 months ago Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
PRESS RELEASE published on 04/25/2023 at 17:59, 2 years 10 months ago EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
PRESS RELEASE published on 04/20/2023 at 10:00, 2 years 11 months ago Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
PRESS RELEASE published on 04/12/2023 at 15:00, 2 years 11 months ago Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
Published on 03/23/2026 at 08:00, 2 hours 15 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 8 hours 15 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 09:19, 56 minutes ago Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 1 hour 15 minutes ago EQS Group launches Risk Management module to support continuous data and AI risk oversight
Published on 03/23/2026 at 08:10, 2 hours 5 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 15 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
